Gerald W. Crabtree
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Gerald W. Crabtree
Gerald W. Crabtree is recorded as CTO at PharmaCyte Biotech, Inc. (PMCB). PharmaCyte Biotech, Inc. reported in an 8-K filed October 14, 2022 that Gerald W. Crabtree resigned as Chief Scientific Officer, effective October 12, 2022. The proxy statement of PharmaCyte Biotech, Inc. reports total compensation of $66,658 for Gerald W. Crabtree in fiscal 2023, including a base salary of $64,695. Disclosed compensation is on record for 3 fiscal years.
“On October 12, 2022 (the “Separation Date”), Gerald W. Crabtree, the Chief Scientific Officer of PharmaCyte Biotech, Inc. (the “Company”), resigned from his position as an employee of the Company.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2020-09-01–present
-
PharmaCyte Biotech, Inc. (PMCB)
Proxy statement
Start not stated–2022-10-12
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at PharmaCyte Biotech, Inc.
Other people whose current roles at this company are on record from its filings.
- Joshua N. Silverman CEO, Chairman, Board Member
- Joshua Silverman CEO
- Daniel Allen Board Member
- Jack E. Stover Board Member
- Jonathan L. Schechter Board Member
- Michael M. Abecassis Board Member
- Robert Weinstein Board Member
- Wayne R. Walker Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | PharmaCyte Biotech, Inc. (PMCB) | Officer | $64,695 | $66,658 |
| 2022 | PharmaCyte Biotech, Inc. (PMCB) | Officer | $128,827 | $136,749 |
| 2021 | PharmaCyte Biotech, Inc. (PMCB) | — | $94,333 | $137,731 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.